{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:04:16Z","timestamp":1774065856213,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejim.2024.04.016","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T07:20:57Z","timestamp":1714720857000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-1083","authenticated-orcid":false,"given":"Antonio","family":"Landi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dik","family":"Heg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8736-7101","authenticated-orcid":false,"given":"Enrico","family":"Frigoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pim A.L.","family":"Tonino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-7447","authenticated-orcid":false,"given":"Suzanne","family":"Pourbaix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"I\u00f1iguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Pinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Lesiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Kala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter C.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.04.016_bib0001","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.04.016_bib0002","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the Academic Research Consortium High Bleeding Risk definition in contemporary PCI patients","volume":"75","author":"Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.04.016_bib0003","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ejim.2024.04.016_bib0004","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/heartjnl-2022-321603","article-title":"Antithrombotic therapy in patients with established atherosclerotic coronary disease","volume":"109","author":"Landi","year":"2023","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ejim.2024.04.016_bib0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjcvp\/pvad032","article-title":"Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease","volume":"9","author":"Valgimigli","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejim.2024.04.016_bib0006","doi-asserted-by":"crossref","DOI":"10.2459\/JCM.0000000000001399","article-title":"Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice","volume":"24","author":"De Servi","year":"2023","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.ejim.2024.04.016_bib0007","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.04.016_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307","article-title":"Application of the Academic Research Consortium High Bleeding Risk criteria in an all-comers registry of percutaneous coronary intervention","volume":"12","author":"Natsuaki","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2024.04.016_bib0009","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.4244\/EIJ-D-20-00345","article-title":"High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry","volume":"16","author":"Nakamura","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ejim.2024.04.016_bib0010","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2020.06.085","article-title":"Trial design principles for patients at high bleeding risk undergoing PCI: JACC scientific expert panel","volume":"76","author":"Capodanno","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.04.016_bib0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2018.10.009","article-title":"Design and rationale of the management of high bleeding risk patients post bioresorbable polymer coated stent implantation with an abbreviated versus standard DAPT regimen (MASTER DAPT) study","volume":"209","author":"Frigoli","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2024.04.016_bib0012","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.016_bib0013","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jcin.2023.01.366","article-title":"Abbreviated or standard antiplatelet therapy in HBR patients","volume":"16","author":"Landi","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2024.04.016_bib0014","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jamacardio.2023.4316","article-title":"Abbreviated or standard dual antiplatelet therapy by sex in patients at high bleeding risk: a prespecified secondary analysis of a randomized clinical trial","volume":"9","author":"Landi","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.04.016_bib0015","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.121.056680","article-title":"Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial","volume":"144","author":"Smits","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.04.016_bib0016","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.04.016_bib0017","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat - Simul Comput"},{"key":"10.1016\/j.ejim.2024.04.016_bib0018","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s00392-019-01585-w","article-title":"Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial","volume":"109","author":"Takahashi","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2024.04.016_bib0019","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1745-6215-12-253","article-title":"Reporting of participant flow diagrams in published reports of randomized trials","volume":"12","author":"Hopewell","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.ejim.2024.04.016_bib0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1745-6215-12-78","article-title":"Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK\/07\/011)","volume":"12","author":"Paramasivan","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.ejim.2024.04.016_bib0021","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13063-017-2413-6","article-title":"Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework","volume":"19","author":"Wilson","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.ejim.2024.04.016_bib0022","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.016_bib0023","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(08)61244-1","article-title":"Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial","volume":"372","author":"Windecker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.04.016_bib0024","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: A pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2024.04.016_bib0025","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jcin.2021.07.016","article-title":"3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation","volume":"14","author":"Mehran","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ejim.2024.04.016_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021965","article-title":"Sex-based differences in bleeding risk after percutaneous coronary intervention and implications for the academic research consortium high bleeding risk criteria","volume":"10","author":"Spirito","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T12:07:41Z","timestamp":1731067661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524001766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":26,"alternative-id":["S0953620524001766"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.04.016","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}